Für den Inhalt der Angaben zeichnet die Projektleitung verantwortlich.
Dieses von der Gebert Rüf Stiftung geförderte Projekt wird von folgenden weiteren Projektpartnern mitgetragen: Swiss Federal Institute of Technology Lausanne, Laboratory of Photonic Materials and Fiber Devices (EPFL STI IMX FIMAP); Swiss Federal Laboratories for Materials Science and Technology, Laboratory for Protection and Physiology (Empa LPP); Swiss Center for Electronics and Microtechnology (CSEM); Clinique Romande de Réadaptation (SUVA); TheranOptics SàrL
Förderbeitrag: CHF 160'000
Dauer: 03.2017 - 09.2018
Handlungsfeld: Pilotprojekte, 1998 - 2018
Dr. Bastien Schyrr
Ecole Polytechnique Fédérale de Lausanne
Laboratory of Photonic Materials and Fiber Devices
1008 Lausanne (Schweiz)
- b.schyrr@theranoptics. com
Chronic wounds such as venous and diabetic foot ulcers are regarded as a silent epidemic, which affects 1 - 2 % of the population and represent 2 - 4 % of healthcare expenses. Correlated with age and the concurrent augmentation in comorbidities such as obesity, cardiovascular diseases and diabetes, they pose an increasing burden to the healthcare system. Despite the proliferation of new guidelines and therapies, chronic wound management remains extremely challenging. First, available wound assessment methods based on visual signs and symptoms provide limited accuracy and strongly rely on the practitioner’s experience. Second, modern wound care technologies acknowledgedly lack sufficient evidence of their impact to objectively support their utilization. As a consequence, wound care efficacy is hindered by non-optimal treatment decisions that rely on trial-and-error approaches and unnecessary medical interventions.
To address these issues, the TheranOptics project, in collaboration with EPFL, Empa and medical experts from the SUVA and HUG, aims at developing a new bioanalytical platform to empower evidence-based medicine in chronic wound care. Our approach relies on fiber-optic sensors as a highly flexible, low-cost device for remote monitoring of the patient’s wound exudate. We exploit recent advances in lab-on-fiber technology to develop an integrated bioanalytical platform, which combines microfluidics, electronics and optics functionalities in a single fiber. The device will be implemented with sensing chemistry specifically developed for wound diagnosis, providing the first bedside bioanalytical tool to support chronic wound management decisions.
Was ist das Besondere an diesem Projekt?
This project proposes a unique combination of technology modules to achieve unmatched functionalities. Microstructured fibers are used as optofluidic module, and modified to integrate optoelectronic functionalities through the incorporation of semiconductor and metal elements in the preform material. This design allows for highly sensitive fluorescence assays in a fully integrated format. Compared to conventional lab-on-chip devices, this unique lab-in-fiber sensing platform possesses the desirable features of small size, potential for low manufacturing cost, and remote monitoring that make it highly advantageous for point-of-care testing.
This project started in March 2017.
No entries yet
No entries yet
Am Projekt beteiligte Personen
Letzte Aktualisierung dieser Projektdarstellung 22.10.2018